羊口疮病毒活载体疫苗和生物制剂的研制现状

doi:10.16431/j.cnki.1671-7236.2015.09.042

摘要/Abstract

摘要： 羊口疮病毒的基因组结构、编码基因复制特性及其在宿主和非宿主体内快速启动机体的免疫反应特点,使其具有作为活病毒疫苗载体的特殊优势。此外,该病毒自身及其编码蛋白的双向免疫调节功能使其具有作为临床使用生物制剂的巨大潜力。作者对基于羊口疮病毒的重组疫苗和生物制剂的研制现状进行了详细的综述,以期为该病毒的疫苗研制、生物制剂研发及临床应用提供参考。

关键词: 羊口疮病毒; 活载体疫苗; 生物制剂

Abstract: Orf virus (ORFV) has special advantages as the live viral vaccination vectors due to its structure of genome, replication characteristics of encoding gene and quick activation of immunoreactions in host and non-host.In addition, ORFV and its coding proteins have huge potential as clinical biological agents for their function as dual immune modulators.Research statuses on recombinant vaccine of ORFV and biological agents were reviewed which would provide the reference for the development and clinical application of vaccination and biological agents.

Key words: Orf virus (ORFV); live vector vaccine; biological agents

中图分类号:

S852.65

张凯照, 于梦, 宁章勇. 羊口疮病毒活载体疫苗和生物制剂的研制现状[J]. 《中国畜牧兽医》---唯一指定的官方网站, 2015, 42(9): 2499-2505.

ZHANG Kai-zhao, YU Meng, NING Zhang-yong. Research Status on the Development of Live Vector Vaccine and Biological Agents of Orf Virus[J]. , 2015, 42(9): 2499-2505.

参考文献

[1] Gallina L,Scagliarini L,Mcinnes C J,et al.Parapoxvirus in goats:Experimental infection and genomic analysis[J].Vet Res Commun,2008,32(Suppl1):S203-S205.

[2] Mercer A A,Ueda N,Friederichs S M,et al.Comparative analysis of genome sequences of three isolates of Orf virus reveals unexpected sequence variation[J].Virus Res,2006,116(1-2):146-158.

[3] Dal Pozzo F,Andrei G,Holy A,et al.Activities of acyclic nucleoside phosphonates against Orf virus in human and ovine cell monolayers and organotypic ovine raft cultures[J].Antimicrob Agents Chemother,2005,49(12):4843-4852.

[4] White K P,Zedek D C,White W L,et al.Orf-induced immunobullous disease:A distinct autoimmune blistering disorder[J].J Am Acad Dermatol,2008,58(1):49-55.

[5] Li W,Hao W,Peng Y,et al.Comparative genomic sequence analysis of Chinese Orf virus strain NA1/11 with other parapoxviruses[J].Arch Virol,2015,160(1):253-266.

[6] Mcguire M J,Johnston S A,Sykes K F.Novel immune-modulator identified by a rapid,functional screen of the parapoxvirus ovis (Orf virus) genome[J].Proteome Sci,2012,10(1):4.

[7] Rziha H,Henkel M,Cottone R,et al.Generation of recombinant parapoxviruses:Non-essential genes suitable for insertion and expression of foreign genes[J].J Biotechnol,2000,83(1-2):137-145.

[8] Rziha H J,Henkel M,Cottone R,et al.Parapoxviruses:Potential alternative vectors for directing the immune response in permissive and non-permissive hosts[J].J Biotechnol,1999,73(2-3):235-242.

[9] Anziliero D,Kreutz L C,Flores E F,et al.Effects of inactivated parapoxvirus ovis on cellular and humoral events of the innate immune response in mice[J].Cell Immunol,2014,289(1-2):36-41.

[10] Fleming S B,Lyttle D J,Sullivan J T,et al.Genomic analysis of a transposition-deletion variant of orf virus reveals a 3.3 kb region of non-essential DNA[J]. J Gen Virol,1995,76 (12):2969-2978.

[11] Meyer H,Sutter G,Mayr A.Mapping of deletions in the genome of the highly attenuated vaccinia virus MVA and their influence on virulence[J]. J Gen Virol,1991,72(5):1031-1038.

[12] Delhon G,Tulman E R,Afonso C L,et al.Genomes of the parapoxviruses ORF virus and bovine papular stomatitis virus[J].J Virol,2004,78(1):168-177.

[13] Ning Z,Peng Y,Hao W,et al.Generation of recombinant Orf virus using an enhanced green fluorescent protein reporter gene as a selectable marker[J].BMC Vet Res,2011,7:80.

[14] Haig D M,Mcinnes C,Deane D,et al.The immune and inflammatory response to Orf virus[J].Comp Immunol Microbiol Infect Dis,1997,20(3):197-204.

[15] Amann R,Rohde J,Wulle U,et al.A new rabies vaccine based on a recombinant ORF virus (parapoxvirus) expressing the rabies virus glycoprotein[J].J Virol,2013,87(3):1618-1630.

[16] Rohde J,Amann R,Rziha H J.New Orf virus (Parapoxvirus) recombinant expressing H5 hemagglutinin protects mice against H5N1 and H1N1 influenza A virus[J]. PLoS One,2013,8(12):e83802.

[17] Voigt H,Merant C,Wienhold D,et al.Efficient priming against classical swine fever with a safe glycoprotein E2 expressing Orf virus recombinant (ORFV VrV-E2)[J].Vaccine,2007,25(31):5915-5926.

[18] Marsland B J,Tisdall D J,Heath D D,et al.Construction of a recombinant orf virus that expresses an Echinococcus granulosus vaccine antigen from a novel genomic insertion site[J].Arch Virol,2003,148(3):555-562.

[19] Fischer T,Planz O,Stitz L,et al.Novel recombinant parapoxvirus vectors induce protective humoral and cellular immunity against lethal herpesvirus challenge infection in mice[J].J Virol,2003,77(17):9312-9323.

[20] van Rooij E M,Rijsewijk F A,Moonen-Leusen H W,et al.Comparison of different prime-boost regimes with DNA and recombinant Orf virus based vaccines expressing glycoprotein D of pseudorabies virus in pigs[J].Vaccine,2010,28(7):1808-1813.

[21] Rohde J,Schirrmeier H,Granzow H,et al.A new recombinant Orf virus (ORFV,Parapoxvirus) protects rabbits against lethal infection with rabbit hemorrhagic disease virus (RHDV)[J].Vaccine,2011,29(49):9256-9264.

[22] Henkel M,Planz O,Fischer T,et al.Prevention of virus persistence and protection against immunopathology after Borna disease virus infection of the brain by a novel Orf virus recombinant[J].J Virol,2005,79(1):314-325.

[23] Pekmezci D,Pekmezci G Z,Guzel M,et al.Efficacy of amitraz plus inactivated parapoxvirus ovis in the treatment of canine generalised demodicosis[J].Vet Rec,2014,174(22):556.

[24] Proksch A L,Unterer S,Truyen U,et al.Efficacy of the paramunity inducer PIND-ORF in the treatment of canine parvovirus infection[J].Vet J,2014,202(2):340-347.

[25] Imlach W,Mccaughan C A,Mercer A A,et al.Orf virus-encoded interleukin-10 stimulates the proliferation of murine mast cells and inhibits cytokine synthesis in murine peritoneal macrophages[J].J Gen Virol,2002,83(5):1049-1058.

[26] Wise L,Mccaughan C,Tan C K,et al.Orf virus interleukin-10 inhibits cytokine synthesis in activated human THP-1 monocytes,but only partially impairs their proliferation[J]. J Gen Virol,2007,88(6):1677-1682.

[27] Wise L M,Stuart G S,Real N C,et al.Orf virus IL-10 accelerates wound healing while limiting inflammation and scarring[J].Wound Repair Regen,2014,22(3):356-367.

[28] Lateef Z,Baird M A,Wise L M,et al.Orf virus-encoded chemokine-binding protein is a potent inhibitor of inflammatory monocyte recruitment in a mouse skin model[J]. J Gen Virol,2009,90(6):1477-1482.

[29] Savory L J,Stacker S A,Fleming S B,et al.Viral vascular endothelial growth factor plays a critical role in orf virus infection[J]. J Virol,2000,74(22):10699-10706.

[30] Deane D,Mcinnes C J,Percival A,et al.Orf virus encodes a novel secreted protein inhibitor of granulocyte-macrophage colony-stimulating factor and interleukin-2[J]. J Virol,2000,74(3):1313-1320.

[31] Deane D,Ueda N,Wise L M,et al.Conservation and variation of the parapoxvirus GM-CSF-inhibitory factor (GIF) proteins[J].J Gen Virol,2009,90(4):970-977.

[32] Friebe A,Siegling A,Friederichs S,et al.Immunomodulatory effects of inactivated Parapoxvirus ovis (ORF virus) on human peripheral immune cells:Induction of cytokine secretion in monocytes and Th1-like cells[J].J Virol,2004,78(17):9400-9411.

[33] Weber O,Siegling A,Friebe A,et al.Inactivated parapoxvirus ovis (Orf virus) has antiviral activity against hepatitis B virus and herpes simplex virus[J].J Gen Virol,2003,84(7):1843-1852.

[34] Nowatzky J,Knorr A,Hirth-Dietrich C,et al.Inactivated Orf virus (Parapoxvirus ovis) elicits antifibrotic activity in models of liver fibrosis[J].Hepatol Res,2013,43(5):535-546.

[35] Paulsen D,Urban A,Knorr A,et al.Inactivated ORF virus shows antifibrotic activity and inhibits human hepatitis B virus (HBV) and hepatitis C virus (HCV) replication in preclinical models[J].PLoS One,2013,8(9):e74605.

[36] Fiebig H H,Siegling A,Volk H D,et al.Inactivated Orf virus (Parapoxvirus ovis) induces antitumoral activity in transplantable tumor models[J].Anticancer Res,2011,31(12):4185-4190.

[37] Rintoul J L,Lemay C G,Tai L H,et al.ORFV:A novel oncolytic and immune stimulating parapoxvirus therapeutic[J].Mol Ther,2012,20(6):1148-1157.

[38] Horohov D W,Breathnach C C,Sturgill T L,et al.In vitro and in vivo modulation of the equine immune response by parapoxvirus ovis[J].Equine Vet J,2008,40(5):468-472.

[39] Ons E,Van Brussel L,Lane S,et al.Efficacy of a Parapoxvirus ovis-based immunomodulator against equine herpesvirus type 1 and Streptococcus equi equi infections in horses[J].Vet Microbiol,2014,173(3-4):232-240.

[40] Anziliero D,Kreutz L C,Flores E F,et al.Effects of inactivated parapoxvirus ovis on cellular and humoral events of the innate immune response in mice[J]. Cell Immunol, 2014,289(1-2):36-41.